SOURCE: Hepregen Corporation

Hepregen Corporation

September 10, 2013 09:15 ET

Hepregen Launches First Rat HepatoPac™ DMPK Assay Kits for Metabolite Identification and Profiling

Companions to Recently Introduced Human HepatoPac™ DMPK Application-Oriented Kit; Combined Use of Rat and Human Products Helps Mitigate Preclinical Pharmaceutical Development Risk

MEDFORD, MA--(Marketwired - September 10, 2013) -  Hepregen Corporation, leader in the development of next generation HepatoPac™ and HepatoMune™ cell-based assay products, announced today the commercial launch of the Company's first application-oriented Rat HepatoPac™ kits designed specifically for use in metabolite identification and profiling. A kit may be ordered that contains either Wistar-Hahn or Sprague-Dawley rat hepatocytes. Much like the recently introduced Hepregen Human HepatoPac™ kit, each of the kits provides customers with a plug-in-ready product, which includes live rat liver cells on a micro-patterned, standard 24-well tissue culture plate that remain fully functional for more than two months.

Data generated by the kits accurately predict the profile of drug metabolite generation in a species that is one of the most important in preclinical drug testing. Moreover, when used in combination with its human liver cell counterpart early in the drug development process, the Human and Rat kits together provide data that helps select the best compounds to advance to pharmaceutical candidate status, mitigating development risks and lowering costs.

Dr. Vincent Zurawski, Hepregen's chief executive officer stated, "The launch of these application-specific kits provides our customers and preclinical CRO partners with a second fully validated option for accurately predicting the metabolic fate of candidate drugs and for evaluating the drug potential of predecessor compounds at all stages of product development. Using our rat and human kits together, drug developers can now evaluate how animal and human data will compare, increasing their confidence in the design of preclinical experiments and improving the efficiency of the drug development process."

About Hepregen Corporation

Hepregen Corporation is the undisputed leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and pharmaceutical, biotherapeutic and diagnostic product development. The Company's micro-liver HepatoPac™ and HepatoMune™ cell-based assay are driving a paradigm shift in drug development. The utility of Hepregen's human, rat, monkey and dog HepatoPac™ and HepatoMune™ products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.

Image Available: http://www.marketwire.com/library/MwGo/2013/9/9/11G007946/Images/d_044_24plate_Rat-570451408518.jpg

Contact Information